Compile Data Set for Download or QSAR
Report error Found 46 Enz. Inhib. hit(s) with all data for entry = 50015261
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50104600((S)-3-{[(R)-1-(3-Piperidin-4-yl-propionyl)-piperid...)
Affinity DataIC50: 0.150nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153559(3-(2-Methyl-pyrimidin-5-yl)-4-[1-(3-5,6,7,8-tetrah...)
Affinity DataIC50: 0.700nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153566(3-Pyridin-3-yl-4-[1-(3-5,6,7,8-tetrahydro-[1,8]nap...)
Affinity DataIC50: 0.800nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153554(3-(3-Fluoro-phenyl)-4-[1-(3-5,6,7,8-tetrahydro-[1,...)
Affinity DataIC50: 1nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153553(3-Benzo[1,3]dioxol-5-yl-4-[1-(3-5,6,7,8-tetrahydro...)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153555(3-(2,4-Dimethoxy-pyrimidin-5-yl)-4-[1-(3-5,6,7,8-t...)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153558(3-Benzo[1,3]dioxol-5-yl-5-{1-[3-(5-hydroxy-1,4,5,6...)
Affinity DataIC50: 1.70nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153570(3-Benzo[1,3]dioxol-5-yl-3-[1-(4-5,6,7,8-tetrahydro...)
Affinity DataIC50: 1.90nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153569(3-Naphthalen-2-yl-4-[1-(3-5,6,7,8-tetrahydro-[1,8]...)
Affinity DataIC50: 1.90nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153573(3-Quinolin-3-yl-3-{[1-(3-5,6,7,8-tetrahydro-[1,8]n...)
Affinity DataIC50: 2.60nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153571(3-({1-[4-(4,5-Dihydro-1H-imidazol-2-ylamino)-butyr...)
Affinity DataIC50: 2.80nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153564(3-({1-[3-(5-Hydroxy-1,4,5,6-tetrahydro-pyridin-2-y...)
Affinity DataIC50: 5.5nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153572(3-Benzo[1,3]dioxol-5-yl-3-({1-[3-(1,4,5,6-tetrahyd...)
Affinity DataIC50: 10.4nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153561(3-({1-[4-(4,5-Dihydro-1H-imidazol-2-ylamino)-butyr...)
Affinity DataIC50: 19nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153561(3-({1-[4-(4,5-Dihydro-1H-imidazol-2-ylamino)-butyr...)
Affinity DataIC50: 19nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153563(3-Benzo[1,3]dioxol-5-yl-4-[1-(4-5,6,7,8-tetrahydro...)
Affinity DataIC50: 20.6nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153567(3-Benzo[1,3]dioxol-5-yl-3-{[1-(3-5,6,7,8-tetrahydr...)
Affinity DataIC50: 21.7nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153568(3-Benzo[1,3]dioxol-5-yl-3-({1-[3-(N''-pyridin-4-yl...)
Affinity DataIC50: 25.3nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153562(3-Benzo[1,3]dioxol-5-yl-3-[1-(3-5,6,7,8-tetrahydro...)
Affinity DataIC50: 28.1nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153568(3-Benzo[1,3]dioxol-5-yl-3-({1-[3-(N''-pyridin-4-yl...)
Affinity DataIC50: 56.4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153565(3-Benzo[1,3]dioxol-5-yl-5-[1-(2-5,6,7,8-tetrahydro...)
Affinity DataIC50: 75nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153571(3-({1-[4-(4,5-Dihydro-1H-imidazol-2-ylamino)-butyr...)
Affinity DataIC50: 79.3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153557(3-Benzo[1,3]dioxol-5-yl-5-[1-(3-5,6,7,8-tetrahydro...)
Affinity DataIC50: 142nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153564(3-({1-[3-(5-Hydroxy-1,4,5,6-tetrahydro-pyridin-2-y...)
Affinity DataIC50: 177nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153572(3-Benzo[1,3]dioxol-5-yl-3-({1-[3-(1,4,5,6-tetrahyd...)
Affinity DataIC50: 209nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153560(3-Benzo[1,3]dioxol-5-yl-5-{1-[4-(pyridin-2-ylamino...)
Affinity DataIC50: 233nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153556(3-Benzo[1,3]dioxol-5-yl-3-[1-(2-5,6,7,8-tetrahydro...)
Affinity DataIC50: 281nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3 (N=1)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153559(3-(2-Methyl-pyrimidin-5-yl)-4-[1-(3-5,6,7,8-tetrah...)
Affinity DataIC50: 965nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153555(3-(2,4-Dimethoxy-pyrimidin-5-yl)-4-[1-(3-5,6,7,8-t...)
Affinity DataIC50: 1.47E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153558(3-Benzo[1,3]dioxol-5-yl-5-{1-[3-(5-hydroxy-1,4,5,6...)
Affinity DataIC50: 1.58E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153561(3-({1-[4-(4,5-Dihydro-1H-imidazol-2-ylamino)-butyr...)
Affinity DataIC50: 1.80E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153561(3-({1-[4-(4,5-Dihydro-1H-imidazol-2-ylamino)-butyr...)
Affinity DataIC50: 1.81E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153553(3-Benzo[1,3]dioxol-5-yl-4-[1-(3-5,6,7,8-tetrahydro...)
Affinity DataIC50: 2.52E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153573(3-Quinolin-3-yl-3-{[1-(3-5,6,7,8-tetrahydro-[1,8]n...)
Affinity DataIC50: 2.85E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153570(3-Benzo[1,3]dioxol-5-yl-3-[1-(4-5,6,7,8-tetrahydro...)
Affinity DataIC50: 4.03E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153563(3-Benzo[1,3]dioxol-5-yl-4-[1-(4-5,6,7,8-tetrahydro...)
Affinity DataIC50: 4.26E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153557(3-Benzo[1,3]dioxol-5-yl-5-[1-(3-5,6,7,8-tetrahydro...)
Affinity DataIC50: 4.36E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153562(3-Benzo[1,3]dioxol-5-yl-3-[1-(3-5,6,7,8-tetrahydro...)
Affinity DataIC50: 6.20E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153566(3-Pyridin-3-yl-4-[1-(3-5,6,7,8-tetrahydro-[1,8]nap...)
Affinity DataIC50: 6.61E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153556(3-Benzo[1,3]dioxol-5-yl-3-[1-(2-5,6,7,8-tetrahydro...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha IIb beta-3 (N=1)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153569(3-Naphthalen-2-yl-4-[1-(3-5,6,7,8-tetrahydro-[1,8]...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153554(3-(3-Fluoro-phenyl)-4-[1-(3-5,6,7,8-tetrahydro-[1,...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153565(3-Benzo[1,3]dioxol-5-yl-5-[1-(2-5,6,7,8-tetrahydro...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153560(3-Benzo[1,3]dioxol-5-yl-5-{1-[4-(pyridin-2-ylamino...)
Affinity DataIC50: 1.09E+4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50153567(3-Benzo[1,3]dioxol-5-yl-3-{[1-(3-5,6,7,8-tetrahydr...)
Affinity DataIC50: 1.57E+4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50104600((S)-3-{[(R)-1-(3-Piperidin-4-yl-propionyl)-piperid...)
Affinity DataIC50: 5.00E+4nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed